Listed

Lantern Pharma Inc.

LTRNNasdaqCIK 1763950HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$3.5m, Q2 FY2026
Net income−$7.1m, Q2 FY2026
Lantern Pharma Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$k2,210Research and development, Q3 FY2023, three months to 2023-09-30$2.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-07, accession 0001493152-24-044010.Report this figure3,573Research and development, Q4 FY2023, three months to 2023-12-31$3.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-27, accession 0001641172-25-000926. Derived: 12-month figure less the 9-month figure.Report this figure4,251Research and development, Q1 FY2024, three months to 2024-03-31$4.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-15, accession 0001641172-25-010547.Report this figure3,889Research and development, Q2 FY2024, three months to 2024-06-30$3.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-13, accession 0001641172-25-023471.Report this figure3,717Research and development, Q3 FY2024, three months to 2024-09-30$3.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figure4,270Research and development, Q4 FY2024, three months to 2024-12-31$4.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-30, accession 0001493152-26-013612. Derived: 12-month figure less the 9-month figure.Report this figure3,264Research and development, Q1 FY2025, three months to 2025-03-31$3.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-15, accession 0001493152-26-023740.Report this figure3,068Research and development, Q2 FY2025, three months to 2025-06-30$3.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure2,437Research and development, Q3 FY2025, three months to 2025-09-30$2.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figure2,745Research and development, Q4 FY2025, three months to 2025-12-31$2.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-30, accession 0001493152-26-013612. Derived: 12-month figure less the 9-month figure.Report this figure1,725Research and development, Q1 FY2026, three months to 2026-03-31$1.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-15, accession 0001493152-26-023740.Report this figure1,791Research and development, Q2 FY2026, three months to 2026-06-30$1.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure
Operating income$k(3,524)Operating income, Q3 FY2023, three months to 2023-09-30−$3.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-07, accession 0001493152-24-044010.Report this figure(4,877)Operating income, Q4 FY2023, three months to 2023-12-31−$4.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-27, accession 0001641172-25-000926. Derived: 12-month figure less the 9-month figure.Report this figure(5,732)Operating income, Q1 FY2024, three months to 2024-03-31−$5.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-15, accession 0001641172-25-010547.Report this figure(5,408)Operating income, Q2 FY2024, three months to 2024-06-30−$5.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-13, accession 0001641172-25-023471.Report this figure(5,180)Operating income, Q3 FY2024, three months to 2024-09-30−$5.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figure(5,896)Operating income, Q4 FY2024, three months to 2024-12-31−$5.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001493152-26-013612. Derived: 12-month figure less the 9-month figure.Report this figure(4,774)Operating income, Q1 FY2025, three months to 2025-03-31−$4.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001493152-26-023740.Report this figure(4,652)Operating income, Q2 FY2025, three months to 2025-06-30−$4.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure(4,350)Operating income, Q3 FY2025, three months to 2025-09-30−$4.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figure(4,203)Operating income, Q4 FY2025, three months to 2025-12-31−$4.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001493152-26-013612. Derived: 12-month figure less the 9-month figure.Report this figure(3,405)Operating income, Q1 FY2026, three months to 2026-03-31−$3.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001493152-26-023740.Report this figure(3,508)Operating income, Q2 FY2026, three months to 2026-06-30−$3.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure
Net income$k(3,161)Net income, Q3 FY2023, three months to 2023-09-30−$3.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-07, accession 0001493152-24-044010.Report this figure(4,186)Net income, Q4 FY2023, three months to 2023-12-31−$4.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-27, accession 0001641172-25-000926. Derived: 12-month figure less the 9-month figure.Report this figure(5,441)Net income, Q1 FY2024, three months to 2024-03-31−$5.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figure(4,960)Net income, Q2 FY2024, three months to 2024-06-30−$5.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figure(4,506)Net income, Q3 FY2024, three months to 2024-09-30−$4.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figure(5,875)Net income, Q4 FY2024, three months to 2024-12-31−$5.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-30, accession 0001493152-26-013612. Derived: 12-month figure less the 9-month figure.Report this figure(4,537)Net income, Q1 FY2025, three months to 2025-03-31−$4.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure(4,331)Net income, Q2 FY2025, three months to 2025-06-30−$4.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure(4,177)Net income, Q3 FY2025, three months to 2025-09-30−$4.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figure(4,074)Net income, Q4 FY2025, three months to 2025-12-31−$4.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-30, accession 0001493152-26-013612. Derived: 12-month figure less the 9-month figure.Report this figure(3,329)Net income, Q1 FY2026, three months to 2026-03-31−$3.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure(7,072)Net income, Q2 FY2026, three months to 2026-06-30−$7.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure
Diluted EPS$ per share(0.29)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-07, accession 0001493152-24-044010.Report this figurenot reported(0.51)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.51 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-15, accession 0001641172-25-010547.Report this figure(0.46)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-13, accession 0001641172-25-023471.Report this figure(0.42)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.42 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figurenot reported(0.42)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.42 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001493152-26-023740.Report this figure(0.40)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.40 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure(0.39)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figurenot reported(0.30)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001493152-26-023740.Report this figure(0.57)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.57 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure
Basic EPS$ per share(0.29)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.29 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-07, accession 0001493152-24-044010.Report this figurenot reported(0.51)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.51 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-15, accession 0001641172-25-010547.Report this figure(0.46)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.46 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-13, accession 0001641172-25-023471.Report this figure(0.42)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.42 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figurenot reported(0.42)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.42 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-15, accession 0001493152-26-023740.Report this figure(0.40)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.40 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure(0.39)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.39 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figurenot reported(0.30)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.30 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-15, accession 0001493152-26-023740.Report this figure(0.57)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.57 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure

Balance sheet

Cash and equivalents$6.7m, Q2 FY2026
Shareholders' equity−$3.2m, Q2 FY2026
Lantern Pharma Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m25.6Cash and equivalents, Q3 FY2023, at 2023-09-30$25.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-08, accession 0001493152-23-039896.Report this figure21.9Cash and equivalents, FY2023, at 2023-12-31$21.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-27, accession 0001641172-25-000926.Report this figure18.4Cash and equivalents, Q1 FY2024, at 2024-03-31$18.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-09, accession 0001493152-24-018422.Report this figure13.0Cash and equivalents, Q2 FY2024, at 2024-06-30$13.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-08, accession 0001493152-24-030766.Report this figure8.1Cash and equivalents, Q3 FY2024, at 2024-09-30$8.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-07, accession 0001493152-24-044010.Report this figure7.5Cash and equivalents, FY2024, at 2024-12-31$7.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-30, accession 0001493152-26-013612.Report this figure6.4Cash and equivalents, Q1 FY2025, at 2025-03-31$6.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-15, accession 0001641172-25-010547.Report this figure6.1Cash and equivalents, Q2 FY2025, at 2025-06-30$6.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-13, accession 0001641172-25-023471.Report this figure8.4Cash and equivalents, Q3 FY2025, at 2025-09-30$8.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figure4.4Cash and equivalents, FY2025, at 2025-12-31$4.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure4.9Cash and equivalents, Q1 FY2026, at 2026-03-31$4.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-15, accession 0001493152-26-023740.Report this figure6.7Cash and equivalents, Q2 FY2026, at 2026-06-30$6.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure
Current assets$m47.4Current assets, Q3 FY2023, at 2023-09-30$47.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-08, accession 0001493152-23-039896.Report this figure43.3Current assets, FY2023, at 2023-12-31$43.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-27, accession 0001641172-25-000926.Report this figure39.5Current assets, Q1 FY2024, at 2024-03-31$39.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0001493152-24-018422.Report this figure35.3Current assets, Q2 FY2024, at 2024-06-30$35.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0001493152-24-030766.Report this figure29.9Current assets, Q3 FY2024, at 2024-09-30$29.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-07, accession 0001493152-24-044010.Report this figure25.2Current assets, FY2024, at 2024-12-31$25.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-30, accession 0001493152-26-013612.Report this figure20.8Current assets, Q1 FY2025, at 2025-03-31$20.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-15, accession 0001641172-25-010547.Report this figure17.2Current assets, Q2 FY2025, at 2025-06-30$17.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-13, accession 0001641172-25-023471.Report this figure13.5Current assets, Q3 FY2025, at 2025-09-30$13.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figure10.8Current assets, FY2025, at 2025-12-31$10.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure7.1Current assets, Q1 FY2026, at 2026-03-31$7.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-15, accession 0001493152-26-023740.Report this figure8.5Current assets, Q2 FY2026, at 2026-06-30$8.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure
Total assets$m47.8Total assets, Q3 FY2023, at 2023-09-30$47.8m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-08, accession 0001493152-23-039896.Report this figure43.6Total assets, FY2023, at 2023-12-31$43.6m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-27, accession 0001641172-25-000926.Report this figure39.7Total assets, Q1 FY2024, at 2024-03-31$39.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0001493152-24-018422.Report this figure35.6Total assets, Q2 FY2024, at 2024-06-30$35.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0001493152-24-030766.Report this figure30.3Total assets, Q3 FY2024, at 2024-09-30$30.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-07, accession 0001493152-24-044010.Report this figure25.6Total assets, FY2024, at 2024-12-31$25.6m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-30, accession 0001493152-26-013612.Report this figure21.1Total assets, Q1 FY2025, at 2025-03-31$21.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-15, accession 0001641172-25-010547.Report this figure17.4Total assets, Q2 FY2025, at 2025-06-30$17.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-13, accession 0001641172-25-023471.Report this figure13.6Total assets, Q3 FY2025, at 2025-09-30$13.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figure11.0Total assets, FY2025, at 2025-12-31$11.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure7.2Total assets, Q1 FY2026, at 2026-03-31$7.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-15, accession 0001493152-26-023740.Report this figure8.6Total assets, Q2 FY2026, at 2026-06-30$8.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure
Current liabilities$m2.3Current liabilities, Q3 FY2023, at 2023-09-30$2.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-08, accession 0001493152-23-039896.Report this figure2.7Current liabilities, FY2023, at 2023-12-31$2.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-27, accession 0001641172-25-000926.Report this figure4.0Current liabilities, Q1 FY2024, at 2024-03-31$4.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0001493152-24-018422.Report this figure4.6Current liabilities, Q2 FY2024, at 2024-06-30$4.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0001493152-24-030766.Report this figure3.6Current liabilities, Q3 FY2024, at 2024-09-30$3.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-07, accession 0001493152-24-044010.Report this figure4.3Current liabilities, FY2024, at 2024-12-31$4.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-30, accession 0001493152-26-013612.Report this figure4.3Current liabilities, Q1 FY2025, at 2025-03-31$4.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-15, accession 0001641172-25-010547.Report this figure4.9Current liabilities, Q2 FY2025, at 2025-06-30$4.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-13, accession 0001641172-25-023471.Report this figure4.0Current liabilities, Q3 FY2025, at 2025-09-30$4.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figure4.5Current liabilities, FY2025, at 2025-12-31$4.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure3.8Current liabilities, Q1 FY2026, at 2026-03-31$3.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-15, accession 0001493152-26-023740.Report this figure4.3Current liabilities, Q2 FY2026, at 2026-06-30$4.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure
Total liabilities$m2.4Total liabilities, Q3 FY2023, at 2023-09-30$2.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-08, accession 0001493152-23-039896.Report this figure2.7Total liabilities, FY2023, at 2023-12-31$2.7m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-27, accession 0001641172-25-000926.Report this figure4.0Total liabilities, Q1 FY2024, at 2024-03-31$4.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-09, accession 0001493152-24-018422.Report this figure4.7Total liabilities, Q2 FY2024, at 2024-06-30$4.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0001493152-24-030766.Report this figure3.7Total liabilities, Q3 FY2024, at 2024-09-30$3.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-07, accession 0001493152-24-044010.Report this figure4.4Total liabilities, FY2024, at 2024-12-31$4.4m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-30, accession 0001493152-26-013612.Report this figure4.3Total liabilities, Q1 FY2025, at 2025-03-31$4.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-15, accession 0001641172-25-010547.Report this figure4.9Total liabilities, Q2 FY2025, at 2025-06-30$4.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-13, accession 0001641172-25-023471.Report this figure4.0Total liabilities, Q3 FY2025, at 2025-09-30$4.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figure4.5Total liabilities, FY2025, at 2025-12-31$4.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure3.8Total liabilities, Q1 FY2026, at 2026-03-31$3.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-15, accession 0001493152-26-023740.Report this figure11.8Total liabilities, Q2 FY2026, at 2026-06-30$11.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure
Shareholders' equity$m45.4Shareholders' equity, Q3 FY2023, at 2023-09-30$45.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-07, accession 0001493152-24-044010.Report this figure40.9Shareholders' equity, FY2023, at 2023-12-31$40.9m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-30, accession 0001493152-26-013612.Report this figure35.8Shareholders' equity, Q1 FY2024, at 2024-03-31$35.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figure30.9Shareholders' equity, Q2 FY2024, at 2024-06-30$30.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figure26.6Shareholders' equity, Q3 FY2024, at 2024-09-30$26.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figure21.2Shareholders' equity, FY2024, at 2024-12-31$21.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure16.8Shareholders' equity, Q1 FY2025, at 2025-03-31$16.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure12.5Shareholders' equity, Q2 FY2025, at 2025-06-30$12.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure9.6Shareholders' equity, Q3 FY2025, at 2025-09-30$9.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figure6.5Shareholders' equity, FY2025, at 2025-12-31$6.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure3.4Shareholders' equity, Q1 FY2026, at 2026-03-31$3.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure(3.2)Shareholders' equity, Q2 FY2026, at 2026-06-30−$3.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure

Cash flow

Operating cash flow−$2.9m, Q2 FY2026
Capital expenditure$1, Q4 FY2025
Lantern Pharma Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(3,612)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$3.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-07, accession 0001493152-24-044010. Derived: 9-month figure less the 6-month figure.Report this figure(3,385)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$3.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-27, accession 0001641172-25-000926. Derived: 12-month figure less the 9-month figure.Report this figure(3,069)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$3.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-15, accession 0001641172-25-010547.Report this figure(5,191)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$5.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-13, accession 0001641172-25-023471. Derived: 6-month figure less the 3-month figure.Report this figure(5,582)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$5.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001493152-25-021927. Derived: 9-month figure less the 6-month figure.Report this figure(3,972)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$4.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001493152-26-013612. Derived: 12-month figure less the 9-month figure.Report this figure(4,376)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$4.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001493152-26-023740.Report this figure(3,937)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$3.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001493152-26-037971. Derived: 6-month figure less the 3-month figure.Report this figure(4,572)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$4.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001493152-25-021927. Derived: 9-month figure less the 6-month figure.Report this figure(2,792)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$2.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001493152-26-013612. Derived: 12-month figure less the 9-month figure.Report this figure(3,773)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$3.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001493152-26-023740.Report this figure(2,941)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$2.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001493152-26-037971. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$k4.8Capital expenditure, Q3 FY2023, three months to 2023-09-30$4.8k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-07, accession 0001493152-24-044010. Derived: 9-month figure less the 6-month figure.Report this figure5.1Capital expenditure, Q4 FY2023, three months to 2023-12-31$5.1k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-27, accession 0001641172-25-000926. Derived: 12-month figure less the 9-month figure.Report this figure2.2Capital expenditure, Q1 FY2024, three months to 2024-03-31$2.2k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-15, accession 0001641172-25-010547.Report this figure4.3Capital expenditure, Q2 FY2024, three months to 2024-06-30$4.3k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-13, accession 0001641172-25-023471. Derived: 6-month figure less the 3-month figure.Report this figure3.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$3.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001493152-25-021927. Derived: 9-month figure less the 6-month figure.Report this figure3.1Capital expenditure, Q4 FY2024, three months to 2024-12-31$3.1k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-30, accession 0001493152-26-013612. Derived: 12-month figure less the 9-month figure.Report this figure1.2Capital expenditure, Q1 FY2025, three months to 2025-03-31$1.2k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-15, accession 0001493152-26-023740.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-14, accession 0001493152-26-037971. Derived: 6-month figure less the 3-month figure.Report this figure0.6Capital expenditure, Q3 FY2025, three months to 2025-09-30$555. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001493152-25-021927. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$1. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-30, accession 0001493152-26-013612. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported
Share repurchases$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)12.42m, Q2 FY2026
Lantern Pharma Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares10.8Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3010,838,888 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-08, accession 0001493152-23-039896.Report this figure10.9Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3110,857,040 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-09, accession 0001493152-24-018422.Report this figure10.9Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3010,857,040 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0001493152-24-030766.Report this figure10.9Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3010,857,366 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-07, accession 0001493152-24-044010.Report this figure10.7Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3110,742,797 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-15, accession 0001641172-25-010547.Report this figure10.8Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3010,758,805 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-13, accession 0001641172-25-023471.Report this figure10.8Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3010,763,351 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figure10.8Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3110,784,725 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-15, accession 0001493152-26-023740.Report this figure10.8Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3010,784,725 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure10.8Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3010,833,393 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001493152-25-021927.Report this figure11.3Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3111,253,030 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-15, accession 0001493152-26-023740.Report this figure12.4Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3012,423,174 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure

Shares outstanding: 12.78mShares outstanding, period not labelled, at 2026-08-1012,784,146 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-14, accession 0001493152-26-037971.Report this figure at Aug 10, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. Listed shows no prices and gives no investment advice.